Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) was up 7.9% during trading on Friday . The company traded as high as $22.32 and last traded at $22.06. Approximately 172,474 shares changed hands during mid-day trading, a decline of 58% from the average daily volume of 407,259 shares. The stock had previously closed at $20.44.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on BCAX. Cantor Fitzgerald assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued an “overweight” rating on the stock. Morgan Stanley assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set an “overweight” rating and a $35.00 price target for the company. Stifel Nicolaus started coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating and a $47.00 price objective on the stock. Finally, TD Cowen assumed coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating for the company.
Get Our Latest Research Report on Bicara Therapeutics
Bicara Therapeutics Stock Performance
Insider Activity
Bicara Therapeutics Company Profile
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Recommended Stories
- Five stocks we like better than Bicara Therapeutics
- How Investors Can Find the Best Cheap Dividend Stocks
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Stock Market Sectors: What Are They and How Many Are There?
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- High Dividend REITs: Are They an Ideal Way to Diversify?
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.